# Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic Cancer

> **NCT05673811** · PHASE2 · COMPLETED · sponsor: **Theriva Biologics SL** · enrollment: 112 (actual)

## Conditions studied

- Pancreatic Adenocarcinoma
- Metastatic

## Interventions

- **DRUG:** Nab-paclitaxel
- **DRUG:** Gemcitabine
- **GENETIC:** VCN-01

## Key facts

- **NCT ID:** NCT05673811
- **Lead sponsor:** Theriva Biologics SL
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-10
- **Primary completion:** 2025-03-28
- **Final completion:** 2025-03-28
- **Target enrollment:** 112 (ACTUAL)
- **Last updated:** 2025-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05673811

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05673811, "Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05673811. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*